Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 7/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150100 | 0.84 | NR1I2 (0.61) | NR1I2CACNA1BPPARGKDM4E | |
| SCHEMBL13401187 | 0.83 | NR1I2 (0.52) | NR1I2CACNA1BPPARG | |
| SCHEMBL8153113 | 0.77 | NR1I2 (0.49) | NR1I2CACNA1BPPARG | |
| SCHEMBL8153127 | 0.77 | CACNA1B (0.64) | NR1I2CACNA1BPPARG | |
| SCHEMBL8151072 | 0.76 | PPARG (0.47) | NR1I2CACNA1BPPARG | |
| SCHEMBL8150545 | 0.75 | CACNA1B (0.76) | NR1I2CACNA1B | |
| SCHEMBL8156333 | 0.72 | NR1I2 (0.75) | NR1I2CACNA1B | |
| SCHEMBL8143706 | 0.70 | NR1I2 (0.64) | NR1I2CACNA1B | |
| SCHEMBL8144031 | 0.70 | NR1I2 (0.67) | NR1I2CACNA1BPPARGKDM4EUSP2 | |
| SCHEMBL8156761 | 0.70 | NR1I2 (0.54) | NR1I2CACNA1BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | NR1I2 1761/4885CACNA1B 13/4885PPARG 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.